ANI Pharmaceuticals’ (ANIP) “Buy” Rating Reaffirmed at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a report issued on Friday,Benzinga reports. They presently have a $86.00 price target on the specialty pharmaceutical company’s stock. Guggenheim’s price target indicates a potential upside of 26.25% from the company’s current price.

Several other equities research analysts also recently issued reports on ANIP. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 8th. Finally, JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $68.12 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business has a 50 day moving average price of $62.34 and a 200 day moving average price of $59.07. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -123.85 and a beta of 0.49. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.00.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,200 shares of company stock valued at $191,776. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of ANIP. US Bancorp DE lifted its holdings in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the period. KBC Group NV increased its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $200,000. Finally, Bridgefront Capital LLC bought a new stake in ANI Pharmaceuticals during the fourth quarter worth about $204,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.